Latest from @CombatCancer on Twitter

Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html

Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html

📢NEXT WEEK📢Prophylactic #peritoneal Management of High-Risk #ColonCancer

🗓️3 NOV-18.30 CEST

🗣Dr @AndreasBrandl8, Dr @alarjosan, Dr Diane Goéré & Dr Pieter Tanis ➡️https://lnkd.in/gNsACYN

#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer @CombatCancer

Laparoscopic cytoreductive surgery and HIPEC for a limited low-grade pseudomyxoma peritonei.
Performed by Dr @alarjosan and team at @HUReinaSofia
👏🏻👏🏻👏🏻👏🏻

📢Webinar Alert📢
Prophylactic #peritoneal Management of High-Risk #ColonCancer

🗓️3 November-18.30 CEST

🗣Dr @AndreasBrandl8, Dr Alvaro-Arjona-Sanchez, Dr Diane Goéré & Dr Pieter Tanis

👉https://www.essoweb.org/courses/

#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer

@cordekroon @HUReinaSofia @ESSOnews @operarelcancer @SWexner @DeliaCortesGuir @FarazKh65499316 @dr_mohammadyami @AndreasBrandl8 @annafagottimd Closed system with CO2 agitation system @CombatCancer @jansenaxel is an option for drug distribution

#HIVEC #EAU20 Data presented at EAU20 shows HIVEC treated BCG unresponsive patients 54% RFS at 24 months. Complete Response Rate for BCG unresponsive CIS patients over 70% at 6 months. Contact us to find out more.

Just in case you missed this trial data presented at AUA20, #HIVEC immediately prior to TURBT shows equivalent recurrence to I-POP but with 100% adherence for HIVEC, 33% greater than for I-POP.https://bit.ly/3fjnHyD

Load More...